OVERVIEW

Antibodies are Y-shaped molecules made up of heavy and light chains that each has a variable and a constant region. The variable regions of both the heavy and light chains are responsible for antigen binding. The constant region of the heavy chain determines the class to which the antibody belongs. Antibodies with the same isotype have the same constant regions.

Monoclonal antibodies (mAbs) have emerged as effective therapeutic treatments for cancer, various auto-immune disorders and other diseases. Hybridoma technology is the earliest successful technology which is robust and lead to a stable production of desired antibodies. However, hybridoma technology requires substantial time, labor, expense, specialized cell culture facilities, the use of animals, and the expertise to prepare and screen large numbers of hybridomas. Recombinant antibody technology is created and has inherent benefits not available in animal-based antibody production methods. Recombinant antibodies are capable of binding to cell-specific antigens and either targeting those cells for destruction or neutralizing any deleterious effects.

A recombinant humanized antibody was used to treat autoimmune. Fig.1 A recombinant humanized antibody was used to treat autoimmune.

RECOMBINANT ANTIBODY ADVANTAGE

No animal immunization Recombinant antibody was developed by cloning antibody genes, heavy chain and light chain gene, into expression vectors. There is no need for animal immunization.

Monovalency Recombinant antibody is highly specific and bind to a single antigen. The affinity is easier to increase to nanomolar or even picomolar levels.

Reproducibility Recombinant antibody is obtained from antibody genes and production process is controlled and reliable.

Short time and high-throughput Recombinant antibody genes are cloned to high-yield expression vectors and express with mammalian cells in as little as 5-7 days. It is also amenable to high-throughput production.

Isotype conversion A desirable antibody or antibody fragment can be easily converted into different antibody isotypes (e.g. IgG1, IgG2, IgG3, IgG4) or different species (e.g. mouse antibody, human antibody, rabbit antibody) by adding appropriate constant domain.

Creative Biolabs has developed extensive collection of recombinant antibodies and provides recombinant antibody customized services.

For more detailed information about our antibodies, please feel free to contact us.

REFERENCES

  1. Ho, S. C.; et al. Generation of monoclonal antibody-producing mammalian cell lines. Pharmaceutical bioprocessing. 2013, 1(1), 71-87.
  2. Echko, M.; et al. Recombinant antibody technology for the production of antibodies without the use of animals. In EMERGING TECHNOLOGIES. (p. 9). 2010.
  3. Karu, A. E.; et al. Recombinant antibody technology. ILAR journal. 1995, 37(3), 132-141.

Small Scale (mg) Transient Transfection

  • cDNA optimization and cloning into transient expression vector
  • Vector transfection of the 293 or CHO cell line
  • Optional culture expansion and antibody expression
  • Collecting supernatant and purification
  • Product quality control
  • Timely updates, and detailed reports

Large Scale (g) Stable Transfection

  • cDNA optimization and cloning into stable expression vector
  • Vector transfection of the 293 or CHO cell line
  • Stable cell pool construction by G418 and Purinomycin selection
  • Subclone screening and detection of antibody expression
  • Optional culture expansion and antibody expression
  • Collecting supernatant and purification
  • Product quality control
  • Timely updates, and detailed reports
For research use only, not directly for clinical use.
© 2007 - 2020 Creative Biolabs NeutraAB. All Rights Reserved

Online Inquiry

  • Verification code